LPTX Insider Trading Activity and SEC Form 4 Filings
LPTX insider trading summary
No open-market insider purchases or sales of Leap Therapeutics, Inc. (LPTX) have been reported on SEC Form 4 in the past 12 months.
Latest LPTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 24, 2021 | BeiGene, Ltd. | 10% Owner | Buy | $7.2M (2,543,800 @ $2.85) |
| Jun 22, 2020 | Perceptive Advisors LLC | 10% Owner | Buy | $3.5M (1,750,000 @ $2.00) |
| Jun 22, 2020 | Perceptive Life Sciences Master Fund Ltd | 10% Owner | Buy | $3.5M (1,750,000 @ $2.00) |
| Jun 22, 2020 | Joseph Edelman | 10% Owner | Buy | $3.5M (1,750,000 @ $2.00) |
| Feb 5, 2019 | Christopher Mirabelli | CEO, President, Chairman | Buy | $1000K (571,428 @ $1.75) |
| Feb 5, 2019 | Douglas E Onsi | CFO, GC, Treasurer & Secretary | Buy | $1000K (571,428 @ $1.75) |
| Feb 5, 2019 | Augustine Lawlor | Chief Operating Officer | Buy | $1000K (571,428 @ $1.75) |
| Feb 5, 2019 | HealthCare Ventures IX, L.P. | 10% Owner | Buy | $1000K (571,428 @ $1.75) |
| Feb 5, 2019 | Healthcare Partners IX, L.P. | 10% Owner | Buy | $1000K (571,428 @ $1.75) |
| Feb 5, 2019 | Healthcare Partners IX, LLC | 10% Owner | Buy | $1000K (571,428 @ $1.75) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.